Quick Answer
Atara Biotherapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $8.48 million for the year ending 2025.
- Atara Biotherapeutics, Inc. showed a decrease of -66.1% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from Atara Biotherapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2012 to 2025 (14 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 14 years of available data (2012 to 2025), Atara Biotherapeutics, Inc.'s Cash And Cash Equivalents At Carrying Value has grown by 101.6%.
- Historical annual values: Fiscal year 2025: $8.48 million | Fiscal year 2024: $25.03 million | Fiscal year 2023: $25.84 million | Fiscal year 2022: $92.94 million | Fiscal year 2021: $106.08 million | Fiscal year 2020: $200.40 million | Fiscal year 2019: $74.32 million | Fiscal year 2018: $60.70 million | Fiscal year 2017: $79.22 million | Fiscal year 2016: $47.97 million | Fiscal year 2015: $23.75 million | Fiscal year 2014: $21.90 million | Fiscal year 2013: $51.62 million | Fiscal year 2012: $4.21 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: